Fig 1.

Efficacy assessment by subject (colors encode renal cell carcinoma [RCC] variants). (A) Swimmer plot depicts individual patients as lines. Arrows indicate patients who remained on therapy. The primary end point for the trial was progression-free survival at 6 months (vertical line). (B) The best radiographic response for 33 evaluable patients treated. Best response was assessed per Response Evaluation Criteria in Solid Tumors 1.1. OR, objective response. (*) Discontinuation due to toxicity. (†) Voluntary withdrawal from study.